NEW YORK, NY--(Marketwire -03\/01\/12)- Biotechnology shares have been on an impressive run of late. Led by the growing popularity in early stage biotechnology companies, the iShares Nasdaq Biotechnology Index Fund is up roughly 20 percent over the last three months. A recent survey from BIO Industry Analysis finds that investors are more focused on early stage companies than later. \"And, this sentiment is also born out by the increase in percentage of investors who indicate that they are willing to invest in small market cap biotechs,\" Alan Eisenberg, executive vice president of emerging companies and business development, explained. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Tibet Pharmaceuticals, Inc. (NASDAQ: TBET - News) & BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX - News). Access to the full company reports can be found at: <\/p>\n
http:\/\/www.paragonreport.com\/TBET<\/a> <\/p>\n http:\/\/www.paragonreport.com\/BPAX<\/a> <\/p>\n Biotech firms continue to negotiate a more challenging regulation process. The FDA Amendments Act of 2007 forced regulators to increase standards for approvals of new drugs, introducing mandatory risk evaluation and mitigation strategies. According to a Pharmaceuticals & Biotechnology report from IMAP, several pharmaceutical firms have altered their drug portfolios from primary care driven blockbusters towards specialties such as oncology, immunology and inflammation, where the medical need is \"so high that prices are more easily accepted by the regulators.\" <\/p>\n The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at http:\/\/www.paragonreport.com<\/a> and get exclusive access to our numerous stock reports and industry newsletters. <\/p>\n Tibet Pharmaceuticals is an emerging pharmaceutical company engaged in the research and manufacturing of modernized traditional Tibetan medicines in China. Earlier this week shares of the company skyrocketed after the company reported that it plans to accept a proposal from its Chairman and Chief Executive Officer Hong Yu to take the company private. Yu offered to buy remaining shares not owned by him for $3.00 a share in cash. <\/p>\n Shares of BioSante also surged this week after the company reported promising Phase I results for its GVAX vaccine for the treatment of pancreatic cancer. BioSante Pharmaceuticals, Inc., a specialty pharmaceutical company, develops products for female sexual health and oncology. <\/p>\n The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http:\/\/www.paragonreport.com\/disclaimer<\/a> <\/p>\n<\/p>\n Excerpt from: NEW YORK, NY--(Marketwire -03\/01\/12)- Biotechnology shares have been on an impressive run of late. Continue reading
\nShares of Tibet Pharmaceuticals and BioSante Pharmaceuticals on the Upswing - Small Market Cap Biotechs Benefit<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"